Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed …

LymphomasB-cell Lymphomas

M.D. Anderson Cancer CenterNCT05773040